Georgia's Online Cancer Information Center

back
Search Trials

All Cancer Clinical Trials in Georgia

Search Trials
All Cancer Clinical Trials
NCI ID Cancer Type Trial Name
Clinical Trial data last updated Apr 7, 2020.
NCI ID Cancer Type Trial Name
1. Use of Definity® Contrast Agent for Ultrasound of Intraocular Tumors
Cancer Type
Eye Cancer
NCI ID
NCT01930968
Protocol IDs
IRB0003943
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Cancer Type
Prostate Cancer
NCI ID
NCT00882609
Protocol IDs
AMI-2008-01
A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) With HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN)
Cancer Type
Head and Neck Cancer
NCI ID
NCT03719690
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
A 5-year Longitudinal Observational Study of the Natural History and Management of Patients With Hepatocellular Carcinoma (HCC)
Cancer Type
NCI ID
NCT02954094
Protocol IDs
TARGET-HCC
NCI-2018-00316
A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol
Cancer Type
NCI ID
NCT03737994
Protocol IDs
Treatment Sites (17)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Atlanta Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - Canton
Canton
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Kennestone
Marietta
Greta Dudley
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Georgia Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Northside Hospital Cancer Institute - Forsyth
Cumming
404-303-3355
University Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
A Clinical Study to Demonstrate Safety and Efficacy of E7777 in Persistent or Recurrent Cutaneous T-Cell Lymphoma
Cancer Type
Lymphoma, Skin Cancer (Non-Melanoma)
NCI ID
NCT01871727
Protocol IDs
E7777-G000-302
NCI-2013-00713
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Cancer Type
Leukemia
NCI ID
NCT01503632
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) with Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed and Refractory Hematologic Malignancies
Cancer Type
Lymphoma, Myelodysplastic Syndromes (MDS)
NCI ID
NCT03696537
Protocol IDs
IUSCC-0652
NCI-2018-02544
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
Cancer Type
Unknown Primary
NCI ID
NCT01349881
Protocol IDs
Treatment Sites (8)
Dwight David Eisenhower Army Medical Center
Augusta
Erik Rupard
706-787-2100
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Nancy N. and J.C. Lewis Cancer & Research Pavilion at St. Joseph's/Candler
Savannah
Alaina Underberg
912-819-5778
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
Phoebe Cancer Center at Phoebe Putney Memorial Hospital
Albany
Dept of Clinical Research
(229) 312-0406
Piedmont Columbus Regional
Columbus
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
A Feasibility Trial of MLN4924 (Pevonedistat,TAK924) Given in Combination with Azacitidine, Fludarabine, and Cytarabine, in Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia or Relapsed Myelodysplastic Syndrome
Cancer Type
Myelodysplastic Syndromes (MDS)
NCI ID
NCT03813147
Protocol IDs
ADVL1712
ADVL1712
NCI-2019-00215
A Four Arm Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, the Combination of Cediranib / Olaparib and the Combination of Olaparib / Wee1 Inhibitor AZD1775 in Women with Recurrent, Persistent or Metastatic Endometrial Cancer (EEC)
Cancer Type
Endometrial Cancer
NCI ID
NCT03660826
Protocol IDs
NRG-GY012
NRG-GY012
NCI-2017-01672
A Genome-Wide Association Study in Participants Experiencing Breast Cancer Events in High-Risk Postmenopausal Women Receiving Selective Estrogen Receptor Modulators on NSABP Trials P-1 and P-2
Cancer Type
Breast Cancer
NCI ID
NCT00967239
Protocol IDs
MC083I
NCI-2009-01112
CDR0000638644
NSABP-MC083I
A Global Randomized Multicenter Phase 3 Trial of JCAR017 Compared to Standard of Care in Adult Subjects With High-risk, Second-line, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas (TRANSFORM).
Cancer Type
Lymphoma
NCI ID
NCT03575351
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (NSC# 102816) to Chemotherapy in Infants with Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement
Cancer Type
Acute Lymphoblastic Leukemia
NCI ID
NCT02828358
Protocol IDs
Treatment Sites (2)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center
Savannah
Joni N. Shortt, RN, BSN, CCRC
912-350-8913
A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)
Cancer Type
Myelodysplastic Syndromes (MDS)
NCI ID
NCT03013998
Protocol IDs
BAML-16-001
NCI-2017-00278
A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
Cancer Type
Lung Cancer
NCI ID
NCT03851445
Protocol IDs
Treatment Sites (14)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - Canton
Canton
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Kennestone
Marietta
Greta Dudley
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Nancy N. and J.C. Lewis Cancer & Research Pavilion at St. Joseph's/Candler
Savannah
Alaina Underberg
912-819-5778
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
A Multiarm, Open-label, Multicenter, Phase 1b / 2 Study to Evaluate Novel Combination Therapies in Subjects With Previously Treated Advanced EGFRm NSCLC
Cancer Type
Lung Cancer
NCI ID
NCT03381274
Protocol IDs
D6070C00004
NCI-2018-00476
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
Cancer Type
Multiple Primaries
NCI ID
NCT01351545
Protocol IDs
Treatment Sites (4)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
Aflac Cancer and Blood Disorders Center of Children’s at Scottish Rite
Atlanta
Karen Querubin, BSN
404-785-2215
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
A Multi-Center Phase Ib / II Trial of Nivolumab / Ipilimumab-Primed Immunotransplant for Relapsed / Refractory Diffuse Large B Cell Lymphoma Patients
Cancer Type
Lymphoma
NCI ID
NCT03305445
Protocol IDs
17-2164
NCI-2018-00677
A Multicenter Phase II Study of Vaccines to Prevent Recurrence in Patients with HER-2 Positive Breast Cancer
Cancer Type
Breast Cancer
NCI ID
NCT03384914
Protocol IDs
MCC-19117
NCI-2018-00290
A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units Manufactured by the National Cord Blood Program and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients
Cancer Type
Hodgkin Lymphoma, Lymphoma, Non-Hodgkin Lymphoma, Skin Cancer (Non-Melanoma)
NCI ID
NCT01656603
Protocol IDs
6637-01
NCI-2016-01676
A Multicenter Study of Hematopoietic Stem Cell Donor Safety and Quality of Life
Cancer Type
Quality of Life
NCI ID
NCT00948636
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
A Multicenter, Open Label Phase I/II Study of CEP-701 (Lestaurtinib) in Adults with Myelofibrosis
Cancer Type
Myelodysplastic Syndromes (MDS)
NCI ID
NCT00668421
Protocol IDs
104
NCI-2012-00298
A Multicenter, Open Label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial
Cancer Type
Unknown Primary
NCI ID
NCT03486873
Protocol IDs
3475-587
NCI-2018-01717
MK-3475-587
2017-004417-42
A Multicenter, Open-Label Phase 1 Study of U3-1402 in Subjects With Metastatic or Unresectable EGFR-mutant Non-small Cell Lung Cancer
Cancer Type
Lung Cancer
NCI ID
NCT03260491
Protocol IDs
U31402-A-U102
NCI-2018-00060
2017-000543-41
A Multicenter, Open-Label Study of CMX001 Treatment of Serious Diseases or Conditions Caused By dsDNA Viruses
Cancer Type
Bone and Soft Tissue (including Sarcoma)
NCI ID
NCT01143181
Protocol IDs
CMX001-350
1986
A Multicenter, Open-label Study to Determine the Maximum Tolerated Dose, Assess the Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-220 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and/or Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCI ID
NCT02773030
Protocol IDs
CC-220-MM-001
NCI-2016-01463
A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)
Cancer Type
Lymphoma
NCI ID
NCT03372057
Protocol IDs
VS-0145-225
NCI-2018-00275
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Trial of Tecemotide Versus Placebo in Subjects With Completed Concurrent Chemo-radiotherapy for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)
Cancer Type
Lung Cancer
NCI ID
NCT02049151
Protocol IDs
Treatment Sites (1)
Phoebe Cancer Center at Phoebe Putney Memorial Hospital
Albany
Dept of Clinical Research
(229) 312-0406
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3 / ITD AML
Cancer Type
NCI ID
NCT02997202
Protocol IDs
Treatment Sites (3)
Georgia Cancer Center at Augusta University
Augusta
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
A Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life, and Resource Utilization of Injectafer vs. Intravenous Iron Standard of Care for the Treatment of Iron Deficiency Anemia (IDA) in an Infusion Center Setting
Cancer Type
Breast Cancer
NCI ID
NCT01950247
Protocol IDs
1VIT13032
A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer Who Either Relapsed or Were Refractory to Prior Chemotherapy
Cancer Type
Lung Cancer
NCI ID
NCT02200757
Protocol IDs
Treatment Sites (9)
Northwest Georgia Oncology Centers - Austell
Austell
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Bremen
Bremen
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Carrollton
Carrollton
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Cartersville
Cartersville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Douglasville
Douglasville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Jasper
Jasper
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Marietta
Marietta
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Paulding
Hiram
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Villa Rica
Villa Rica
Mary Gilley
770-281-5131
A Multi-Center, Randomized, Phase III Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Relapsed Follicular Non-Hodgkin's Lymphoma
Cancer Type
Non-Hodgkin Lymphoma
NCI ID
NCT00078598
Protocol IDs
CCBX001-049
A Multi-Cohort Phase 1b Clinical Trial of Rituximab in Combination with Immunotherapy in Untreated and Previously Treated Follicular Lymphoma
Cancer Type
NCI ID
NCT03636503
Protocol IDs
18-311
NCI-2018-02767
A Multinational, Randomized, Open-Label Phase III Study of Custirsen (TV-1011/OGX-011) In Combination With Docetaxel Versus Docetaxel As A Second-Line Treatment In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer
Cancer Type
Lung Cancer
NCI ID
NCT01630733
Protocol IDs
TV1011-LC-303
2012-002447-14
A Multi-site, Prospective, Observational Study in US Patients with Advanced Melanoma
Cancer Type
Melanoma
NCI ID
Protocol IDs
CA184-199
IMPULSE
BMS CA184-199
A Non-randomized, Open-label, Multi-center, Phase I / II Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Copanlisib in Pediatric Patients With Relapsed / Refractory Solid Tumors or Lymphoma
Cancer Type
Bone and Soft Tissue (including Sarcoma), Ewing Sarcoma, Lymphoma, Neuroblastoma
NCI ID
NCT03458728
Protocol IDs
19176
NCI-2018-00809
2017-000383-15
A Novel Method of Screening for Ovarian Cancer Using Gynecologic Fluids and Mucus
Cancer Type
NCI ID
NCT01787656
Protocol IDs
USA-MCI GON-1.04
NCI-2015-00690
13-005
A Pediatric Brain Tumor Consortium Phase I / II and Surgical Study of CX-4945 in Patients with Recurrent SHH Medulloblastoma
Cancer Type
NCI ID
NCT03904862
Protocol IDs
PBTC-053
PBTC-053
NCI-2019-00180
A Phase 1 / 1b First-In-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 Monotherapy and in Combination With Nivolumab in Subjects With Advanced Solid Tumors
Cancer Type
Unknown Primary
NCI ID
NCT02637531
Protocol IDs
IPI-549-01
NCI-2016-00132
A Phase 1 / 1b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX 101) in Children and Adolescents With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions
Cancer Type
Neuroblastoma
NCI ID
NCT02650401
Protocol IDs
RXDX-101-03
NCI-2016-00924
A Phase 1 / 2 Open Label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Cancer Type
NCI ID
NCT03850574
Protocol IDs
HM-FLTI-101
NCI-2019-06837
A Phase 1 / 2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab (MEDI4736) Plus the Toll-like Receptor Agonist PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers
Cancer Type
Melanoma
NCI ID
NCT02643303
Protocol IDs
LUD2014-011
NCI-2017-01766
A Phase 1 / 2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL / SLL) or Non-Hodgkin's Lymphoma (NHL)
Cancer Type
Leukemia, Lymphoma, Non-Hodgkin Lymphoma
NCI ID
NCT03740529
Protocol IDs
LOXO-BTK-18001
NCI-2019-02015
A Phase 1 / 2 Study of Pembrolizumab plus Pralatrexate for Treatment of Relapsed or Refractory Peripheral T-Cell Lymphomas
Cancer Type
NCI ID
NCT03598998
Protocol IDs
17501
NCI-2018-01420
A Phase 1 / 2 Study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects With Previously Treated NTRK Fusion Cancers
Cancer Type
NCI ID
NCT03215511
Protocol IDs
20810
NCI-2017-01629
2017-004246-20
LOXO-EXT-17005
A Phase 1 / 2 Study of TPX-0046, A Novel Oral RET / SRC Inhibitor in Adult Subjects With Advanced / Metastatic Solid Tumors Harboring Oncogenic RET Fusions or Mutations
Cancer Type
NCI ID
NCT04161391
Protocol IDs
TPX-0046-01
NCI-2019-08596
A Phase 1 / 2 Study of VX15 / 2503 in Children, Adolescents, or Young Adults with Recurrent or Relapsed Solid Tumors
Cancer Type
Bone and Soft Tissue (including Sarcoma)
NCI ID
NCT03320330
Protocol IDs
ADVL1614
ADVL1614
NCI-2017-01103
A Phase 1 / 2, Multicenter, Dose-Escalation and Expansion Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects With Relapsed or Refractory Multiple Myeloma
Cancer Type
Lymphoma, Multiple Myeloma
NCI ID
NCT03314181
Protocol IDs
M15-654
NCI-2018-00251
2017-002099-26
A Phase 1 / 2, Multicenter, Open-label Study of FT-2102 as a Single Agent and in Combination With Azacitidine or Cytarabine in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome With an IDH1 Mutation
Cancer Type
Leukemia, Myelodysplastic Syndromes (MDS)
NCI ID
NCT02719574
Protocol IDs
2102-HEM-101
NCI-2016-00637
A Phase 1 / 2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C
Cancer Type
Unknown Primary
NCI ID
NCT03600883
Protocol IDs
20170543
NCI-2018-01725
A Phase 1 / 2, Open-Label Study of ADXS-503 Alone and in Combination With Pembrolizumab in Subjects With Metastatic Squamous or Non-Squamous Non-Small Cell Lung Cancer
Cancer Type
Lung Cancer, Unknown Primary
NCI ID
NCT03847519
Protocol IDs
ADXS-503-101
NCI-2019-01784
A Phase 1 / 2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies - (FIGHT-101)
Cancer Type
Myelodysplastic Syndromes (MDS)
NCI ID
NCT02393248
Protocol IDs
INCB 54828-101
NCI-2015-00611
A Phase 1 / 2, Open-Label, Multicenter Study to Investigate the Safety and Preliminary Efficacy of NKTR-214 in Combination With Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
Cancer Type
NCI ID
NCT03138889
Protocol IDs
Treatment Sites (1)
Georgia Cancer Center at Augusta University
Augusta
A Phase 1 / 2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-262 in Combination With NKTR-214 and in Combination With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies
Cancer Type
Melanoma
NCI ID
NCT03435640
Protocol IDs
17-262-01
NCI-2018-00619
A Phase 1 / 2a Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-573 (Formerly TEV-48573) Administered Intravenously as a Single Agent in Patients With Refractory Multiple Myeloma
Cancer Type
Lymphoma, Multiple Myeloma
NCI ID
NCT03215030
Protocol IDs
TAK-573-1501
NCI-2017-01894
U1111-1195-8134
TV48573-ONC-10128
A Phase 1 / 2a Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients with Mantle Cell Lymphoma (MCL)
Cancer Type
Lymphoma
NCI ID
NCT03153202
Protocol IDs
17-0554
NCI-2017-01538
A Phase 1 and Phase II and Re-Treatment Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma
Cancer Type
NCI ID
NCT01089101
Protocol IDs
PBTC-029
PBTC-029
NCI-2012-03173
CDR667932
PBTC-029B
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors
Cancer Type
Unknown Primary
NCI ID
NCT02817633
Protocol IDs
4020-01-001
NCI-2016-01254
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
Cancer Type
Unknown Primary
NCI ID
NCT02715284
Protocol IDs
4010-01-001
NCI-2016-01910
A Phase 1 Dose-escalation Study of Radio- Labeled Antibody, FF-21101(90Y) for the Treatment of Advanced Cancer
Cancer Type
NCI ID
NCT02454010
Protocol IDs
FF21101US101
NCI-2015-01552
A Phase 1 Multicenter, Open-label Study to Assess the Safety, Pharmacokinetics and Preliminary Efficacy of CC-92480 in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
Cancer Type
Lymphoma, Multiple Myeloma
NCI ID
NCT03374085
Protocol IDs
CC-92480-MM-001
NCI-2018-00132
U1111-1205-3650
2017-001236-19
A Phase 1 Multiple Ascending Dose Study of DS-3201b in Subjects With Lymphomas
Cancer Type
Leukemia, Lymphoma, Non-Hodgkin Lymphoma
NCI ID
NCT02732275
Protocol IDs
DS3201-A-J101
NCI-2019-00366
A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®14045 in Patients With CD123-Expressing Hematologic Malignancies
Cancer Type
Leukemia, Lymphoma, Myelodysplastic Syndromes (MDS), Skin Cancer (Non-Melanoma)
NCI ID
NCT02730312
Protocol IDs
XmAb14045-01
NCI-2016-00916
A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®18087 in Subjects With Advanced Neuroendocrine and Gastrointestinal Stromal Tumors
Cancer Type
Colon/Rectal Cancer
NCI ID
NCT03411915
Protocol IDs
XmAb18087-01
NCI-2018-00217
A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
Cancer Type
Endometrial Cancer
NCI ID
NCT03517488
Protocol IDs
XmAb20717-01
NCI-2018-00935
DUET-2
A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination With Pembrolizumab in Subjects With Selected Advanced Solid Tumors (DUET-4)
Cancer Type
Breast Cancer, Cervical Cancer, Colon/Rectal Cancer, Eye Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Melanoma, Pancreatic Cancer, Prostate Cancer , Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Unknown Primary
NCI ID
NCT03849469
Protocol IDs
XmAb22841-01
NCI-2019-02498
DUET-4
A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®23104 in Subjects With Selected Advanced Solid Tumors
Cancer Type
Lung Cancer
NCI ID
NCT03752398
Protocol IDs
XmAb23104-01
NCI-2019-00828
DUET-3
A Phase 1 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 701 in Subjects With Multiple Myeloma
Cancer Type
Lymphoma, Multiple Myeloma
NCI ID
NCT03287908
Protocol IDs
20170122
NCI-2017-02084
2017-001997-41
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
Cancer Type
Lymphoma, Multiple Myeloma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT03424603
Protocol IDs
STRO-001-BCM1
NCI-2018-00484
A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 757 in Subjects With Small Cell Lung Cancer
Cancer Type
Lung Cancer, Skin Cancer (Non-Melanoma)
NCI ID
NCT03319940
Protocol IDs
20160323
NCI-2017-02043
A Phase 1 Study of ABI-009 (NAB-RAPAMYCIN) in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors as a Single Agent and in Combination with Temozolomide and Irinotecan
Cancer Type
Unknown Primary
NCI ID
NCT02975882
Protocol IDs
ADVL1514
ADVL1514
NCI-2016-01412
ADVL1514
A Phase 1 Study of ALKS 4230 Administered Subcutaneously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (ARTISTRY-2)
Cancer Type
Unknown Primary
NCI ID
NCT03861793
Protocol IDs
ALKS 4230-001
NCI-2019-02348
A Phase 1 Study of ASP1951 in Subjects With Advanced Solid Tumors
Cancer Type
Lung Cancer, Prostate Cancer , Unknown Primary
NCI ID
NCT03799003
Protocol IDs
1951-CL-0101
NCI-2019-02414
A Phase 1 Study of bb21217, an Anti-BCMA CAR T Cell Drug Product, in Relapsed and / or Refractory Multiple Myeloma
Cancer Type
Lymphoma, Multiple Myeloma
NCI ID
NCT03274219
Protocol IDs
CRB-402
NCI-2017-01861
A Phase 1 Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (advSM) and Relapsed or Refractory Myeloid Malignancies
Cancer Type
NCI ID
NCT02561988
Protocol IDs
BLU-285-2101
NCI-2016-00075
2015-001661-12
A Phase 1 Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies
Cancer Type
Head and Neck Cancer, Lung Cancer
NCI ID
NCT03329950
Protocol IDs
Treatment Sites (2)
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
A Phase 1 Study of DS-3032b in Combination With Quizartinib in Subjects With FLT3-ITD Mutant Acute Myeloid Leukemia That Are Relapsed / Refractory, or Newly Diagnosed and Unfit for Intensive Chemotherapy
Cancer Type
NCI ID
NCT03552029
Protocol IDs
DS3032-A-U105
NCI-2018-01454
A Phase 1 Study of Ipilimumab in Combination with Decitabine in Relapsed or Refractory Myelodysplastic Syndrome / Acute Myeloid Leukemia
Cancer Type
Myelodysplastic Syndromes (MDS)
NCI ID
NCT02890329
Protocol IDs
Treatment Sites (14)
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Atlanta Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - Canton
Canton
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Kennestone
Marietta
Greta Dudley
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Georgia Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Northside Hospital Cancer Institute - Forsyth
Cumming
404-303-3355
University Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
A Phase 1 Study of MK-3475 (Pembrolizumab) in Combination with Recombinant Interleukin-12 in Patients with Solid Tumors
Cancer Type
Unknown Primary
NCI ID
NCT03030378
Protocol IDs
10061
10061
NCI-2017-00091
HCC 17-003
A Phase 1 Study of Oral LOXO-292 in Patients With Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors With Increased RET Activity
Cancer Type
Colon/Rectal Cancer, Lung Cancer, Skin Cancer (Non-Melanoma), Thyroid Cancer, Unknown Primary
NCI ID
NCT03157128
Protocol IDs
LOXO-RET-17001
NCI-2017-00976
2017-000800-59
A Phase 1 Study of Palbociclib in Combination with Cisplatin or Carboplatin in Advanced Solid Malignancies
Cancer Type
Unknown Primary
NCI ID
NCT02897375
Protocol IDs
Winship3263-16
NCI-2016-01037
IRB00089583
A Phase 1 Study of Pevonedistat (MLN4924), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors
Cancer Type
Lymphoma
NCI ID
NCT03323034
Protocol IDs
ADVL1615
ADVL1615
NCI-2017-01229
ADVL1615
A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, in Patients With Advanced Solid Malignancies and Lymphoma With an Expansion in Select Malignancies
Cancer Type
Unknown Primary
NCI ID
NCT02922764
Protocol IDs
RGX-104-001
NCI-2017-00226
A Phase 1 Study of Selinexor (KPT-330), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
Cancer Type
Brain Cancer , Eye Cancer, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT02323880
Protocol IDs
ADVL1414
NCI-2014-02410
A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
Cancer Type
Bone and Soft Tissue (including Sarcoma), Chondrosarcoma
NCI ID
NCT02601937
Protocol IDs
EZH-102
NCI-2015-02224
A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Cancer Type
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Leukemia, Lymphoma, Neuroblastoma
NCI ID
NCT03236857
Protocol IDs
M13-833
NCI-2017-02027
2017-000439-14
A PHASE 1 STUDY TO EVALUATE THE EFFECT OF HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS AND SAFETY OF LORLATINIB IN ADVANCED CANCER PATIENTS
Cancer Type
Lymphoma, Unknown Primary
NCI ID
NCT03726333
Protocol IDs
B7461009
NCI-2019-01060
HEPATIC IMPAIRMENT
lorlatinib HEPATIC IMPAIRMENT
A Phase 1 Study Using Nab-Paclitaxel (Abraxane®) in Combination with Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors
Cancer Type
NCI ID
NCT03507491
Protocol IDs
AFLACST1603
NCI-2018-00465
IRB00098777
A Phase 1 Study Using Simvastatin in Combination With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors
Cancer Type
Unknown Primary
NCI ID
NCT02390843
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
A Phase 1 Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351 (Daunorubicin and Cytarabine) Liposome for Injection Treatment in Adult Patients With Hematologic Malignancies
Cancer Type
Lymphoma, Myelodysplastic Syndromes (MDS)
NCI ID
NCT03555955
Protocol IDs
Treatment Sites (2)
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
A Phase 1 Trial using Everolimus in Combination with Nelarabine, Cyclophosphamide and Etoposide in Relapsed T cell Lymphoblastic Leukemia / Lymphoma
Cancer Type
Lymphoma
NCI ID
NCT03328104
Protocol IDs
AflacLL1602
NCI-2017-01717
A Phase 1, Dose Escalation and Expansion Study of Engineered Donor Grafts Derived From Mobilized Peripheral Blood (OrcaGraft), With Single Agent Graft Versus-host Disease Prophylaxis, in Recipients Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies
Cancer Type
Myelodysplastic Syndromes (MDS)
NCI ID
NCT03802695
Protocol IDs
OGFT001-001
NCI-2019-01953
A Phase 1, First in Human, Dose Escalation Study of MGD006, a CD123 x CD3 Dual Affinity Re-Targeting (DART) Bi-Specific Antibody Based Molecule, in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Cancer Type
Leukemia
NCI ID
NCT02152956
Protocol IDs
CP-MGD006-01
NCI-2014-01526
A Phase 1, First-in-Human, Open-Label, Dose Escalation and Expansion Study of CUE-101 Monotherapy in Patients With HPV+ Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Cancer Type
Skin Cancer (Non-Melanoma), Unknown Primary
NCI ID
NCT03978689
Protocol IDs
Cue-101-01
NCI-2019-04589
A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R / R) B-cell Non-Hodgkin Lymphoma (NHL)
Cancer Type
Lymphoma, Non-Hodgkin Lymphoma
NCI ID
NCT02631044
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-689 in Patients With Relapsed or Refractory Lymphoma
Cancer Type
NCI ID
NCT03786926
Protocol IDs
2018-689-US001
NCI-2019-01158
2018-689-00US1
A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (Anti-LAG-3 mAb) Administered Alone or in Combination With REGN2810 (Anti-PD-1 mAb) in Patients With Advanced Malignancies
Cancer Type
Lymphoma, Unknown Primary
NCI ID
NCT03005782
Protocol IDs
R3767-ONC-1613
NCI-2017-00409
2016-002789-30
A Phase 1, Open-label, Multi-center, Dose Escalation and Dose Expansion Study of NKTR-255 as a Single Agent in Relapsed or Refractory Hematological Malignancies and in Combination With Daratumumab as a Salvage Regimen for Multiple Myeloma
Cancer Type
NCI ID
NCT04136756
Protocol IDs
18-255-02
NCI-2019-07642
A Phase 1, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD5991 in Subjects With Relapsed or Refractory Haematologic Malignancies
Cancer Type
Hodgkin Lymphoma, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes (MDS), Non-Hodgkin Lymphoma, Skin Cancer (Non-Melanoma), Unknown Primary
NCI ID
NCT03218683
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers
Cancer Type
Oral Cancer
NCI ID
NCT02655822
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies
Cancer Type
Unknown Primary
NCI ID
NCT02587598
Protocol IDs
INCB 53914-101
NCI-2015-01975
A Phase 1/2 Study of MK-1775 in Combination With Irinotecan in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors
Cancer Type
Unknown Primary
NCI ID
NCT02095132
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-214 and Nivolumab in Patients With Select Locally Advanced or Metastatic Solid Tumor Malignancies.
Cancer Type
Kidney Cancer, Lung Cancer, Melanoma
NCI ID
NCT02983045
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B Cell or T Cell Non-Hodgkin Lymphoma (NHL)
Cancer Type
Non-Hodgkin Lymphoma
NCI ID
NCT01994382
Protocol IDs
Treatment Sites (1)
Gwinnett Medical Center
Lawrenceville
404-851-2340
A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (BMS-936558, Anti-PD-1 Monoclonal Antibody) in Advanced Malignant Tumors
Cancer Type
Unknown Primary
NCI ID
NCT02658890
Protocol IDs
Treatment Sites (2)
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
A Phase 1b / 2 Open Label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor CB-839 in Combination With the PARP Inhibitor Talazoparib in Patients With Advanced or Metastatic Solid Tumors
Cancer Type
Breast Cancer, Kidney Cancer, Unknown Primary
NCI ID
NCT03875313
Protocol IDs
CX-839-011
NCI-2019-02256
A Phase 1b / 2 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics,Pharmacodynamics, and Efficacy of AMG 592 inAdult Subjects With Steroid Refractory Chronic Graft Versus Host Disease
Cancer Type
NCI ID
NCT03422627
Protocol IDs
20160283
NCI-2018-00330
2017-000763-33
A Phase 1b / 2 Open-label Study To Evaluate Safety, Clinical Activity, Pharmacokinetics And Pharmacodynamics Of Avelumab (msb0010718c) In Combination With Other Cancer Immunotherapies In Patients With Advanced Malignancies
Cancer Type
Breast Cancer, Lung Cancer, Melanoma, Ovarian Cancer, Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Unknown Primary
NCI ID
NCT02554812
Protocol IDs
B9991004
NCI-2015-02263
2015-002552-27
JAVELIN MEDLEY
s16-02110
A Phase 1b / 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of EQ001 in Subjects With Newly Diagnosed Acute Graft Versus Host Disease
Cancer Type
Bone and Soft Tissue (including Sarcoma)
NCI ID
NCT03763318
Protocol IDs
EQ001-aGVHD-001
NCI-2019-01124
A Phase 1b / 2, Open Label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination With CDK4 / 6 Inhibitor Palbociclib in Patients With Advanced or Metastatic Solid Tumors
Cancer Type
NCI ID
NCT03965845
Protocol IDs
CX-839-012
NCI-2019-05094
A Phase 1b / 2, Open-Label, Multicenter Dose-Escalation and Dose-Expansion Study of the Combination of RMC-4630 and Cobimetinib in Adult Participants With Relapsed / Refractory Solid Tumors With Specific Genomic Aberrations
Cancer Type
Unknown Primary
NCI ID
NCT03989115
Protocol IDs
RMC-4630-02
NCI-2019-04826
A Phase 1b / 2a Pilot Randomized Study to Evaluate the Safety and Tolerability of Autologous T-Cells Expressing Enhanced TCRs (T Cell Receptors) Specific for NY-ESO-1 / LAGE-1a (GSK3377794) Alone, or in Combination With Pembrolizumab in HLA-A2+ Participants With NY-ESO-1- or LAGE-1a-Positive Advanced or Recurrent Non-Small Cell Lung Cancer
Cancer Type
Lung Cancer, Unknown Primary
NCI ID
NCT03709706
Protocol IDs
208471
NCI-2018-03721
A Phase 1b Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Immune Checkpoint Inhibitor (CPI) Therapy for Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer
Cancer Type
Bladder Cancer, Kidney Cancer, Unknown Primary
NCI ID
NCT03288545
Protocol IDs
SGN22E-002
NCI-2017-01927
A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
Cancer Type
NCI ID
NCT03319628
Protocol IDs
XMT-1536-1
NCI-2018-00402
A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With B-Cell Lymphoid Malignancies
Cancer Type
Leukemia, Lymphoma
NCI ID
NCT03420183
Protocol IDs
CIRM-0001
NCI-2018-00270
A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with B-Cell Lymphoid Malignancies
Cancer Type
NCI ID
NCT03088878
Protocol IDs
170127
NCI-2018-01703
NCT03420183
A Phase 2 / 3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study)
Cancer Type
Myelodysplastic Syndromes (MDS)
NCI ID
NCT03805789
Protocol IDs
CSL964_2001
NCI-2019-03310
2018-000329-29
A Phase 2 Efficacy and Safety Trial of ADU-S100 and Anti-PD1 in Adults With Head and Neck Cancer
Cancer Type
Unknown Primary
NCI ID
NCT03937141
Protocol IDs
ADU-CL-20
NCI-2019-04759
A Phase 2 Front-Line PET / CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)
Cancer Type
Lymphoma
NCI ID
NCT03712202
Protocol IDs
18157
NCI-2018-01592
A Phase 2 Randomized Study of Irinotecan / Temozolomide / Dinutuximab with or without Eflornithine (DFMO) in Children with Relapsed, Refractory or Progressive Neuroblastoma
Cancer Type
Neuroblastoma
NCI ID
NCT03794349
Protocol IDs
ANBL1821
ANBL1821
NCI-2018-03377
A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma
Cancer Type
Bone and Soft Tissue (including Sarcoma)
NCI ID
NCT03141684
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
A Phase 2 Study of Atezolizumab and Cobimetinib in PD-1 / PD-L1 Inhibitor Resistant or Refractory Non-Small Cell Lung Cancer
Cancer Type
NCI ID
NCT03600701
Protocol IDs
10166
10166
NCI-2017-01812
A Phase 2 Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) after Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)
Cancer Type
NCI ID
NCT03919071
Protocol IDs
ACNS1723
ACNS1723
NCI-2019-02289
A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations
Cancer Type
NCI ID
NCT04083976
Protocol IDs
CR108661
NCI-2019-07959
42756493CAN2002
2019-002113-19
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
Cancer Type
Lymphoma
NCI ID
NCT02981628
Protocol IDs
AALL1621
AALL1621
NCI-2016-01494
AALL1621
A Phase 2 Study of Lenvatinib in Combination with Radioactive Iodine Therapy in Patients with Progressive RAI-Sensitive Differentiated Thyroid Cancer
Cancer Type
Thyroid Cancer
NCI ID
NCT03506048
Protocol IDs
Winship4271-18
NCI-2018-00144
IRB00101617
A Phase 2 Study of Neoadjuvant Cabozantinib in Patients with Locally Advanced Non-Metastatic Clear Cell Renal Cell Carcinoma
Cancer Type
Kidney Cancer, Unknown Primary
NCI ID
NCT04022343
Protocol IDs
Winship4643-19
NCI-2019-02253
IRB00110583
A Phase 2 Study of Olaparib in Combination With Pembrolizumab in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) and / or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer
Cancer Type
NCI ID
NCT04123366
Protocol IDs
7339-007
NCI-2019-08758
2019-001745-40
MK-7339-007
KEYLYNK-007
A Phase 2 Study of Olaparib Monotherapy in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer
Cancer Type
Unknown Primary
NCI ID
NCT03742895
Protocol IDs
7339-002
NCI-2018-03519
2018-003007-19
MK-7339-002
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Cancer Type
NCI ID
NCT02724579
Protocol IDs
ACNS1422
ACNS1422
NCI-2016-00150
ACNS1422
A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia
Cancer Type
Acute Lymphoblastic Leukemia
NCI ID
NCT02723994
Protocol IDs
INCB 18424-269
NCI-2016-01687
AALL1521
A Phase 2 Study of the MEK Inhibitor Trametinib (NSC# 763093) in Children with Relapsed or Refractory Juvenile Myelomonocytic Leukemia
Cancer Type
Myelodysplastic Syndromes (MDS)
NCI ID
NCT03190915
Protocol IDs
ADVL1521
ADVL1521
NCI-2017-00921
ADVL1521
A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors
Cancer Type
NCI ID
NCT03212274
Protocol IDs
10129
10129
NCI-2017-01182
2000023083
A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
Cancer Type
Myelodysplastic Syndromes (MDS)
NCI ID
NCT02718300
Protocol IDs
INCB 50465-201
NCI-2016-01146
A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600E Mutations
Cancer Type
NCI ID
NCT03581292
Protocol IDs
ACNS1721
ACNS1721
NCI-2018-01361
A Phase 2 Study To Evaluate Safety And Anti-tumor Activity Of Avelumab In Combination With Talazoparib In Patients With Brca Or Atm Mutant Tumors
Cancer Type
Unknown Primary
NCI ID
NCT03565991
Protocol IDs
Treatment Sites (11)
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - Canton
Canton
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Kennestone
Marietta
Greta Dudley
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma
Cancer Type
NCI ID
NCT02940301
Protocol IDs
OSU-16077
NCI-2016-01473
2016C0122
A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants With Advanced Gastric Cancer (FRACTION-Gastric Cancer)
Cancer Type
Stomach/ Gastric Cancer
NCI ID
NCT02935634
Protocol IDs
CA018-003
NCI-2017-00025
2016-002807-24
A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Recurrent, Metastatic or Persistent Cervical Carcinoma
Cancer Type
Cervical Cancer
NCI ID
NCT03108495
Protocol IDs
Treatment Sites (1)
Georgia Cancer Center at Augusta University
Augusta
A Phase 2, Multicenter, Open-label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects With Relapsed / Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)
Cancer Type
Ewing Sarcoma
NCI ID
NCT03441360
Protocol IDs
E7389-G000-223
NCI-2018-00749
A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of CDX-3379 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma
Cancer Type
Unknown Primary
NCI ID
NCT03254927
Protocol IDs
CDX3379-04
NCI-2017-01709
A Phase 2, Multicohort, Open-label, Multicenter Study to Determine the Efficacy and Safety of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma Having Progressed Within One Year of Initial Treatment (KarMMa-2)
Cancer Type
Lymphoma, Multiple Myeloma
NCI ID
NCT03601078
Protocol IDs
BB2121-MM-002
NCI-2018-01730
U1111-1216-4209
2018-000264-28
A Phase 2, Non-randomized, Open Label, Single Arm, Multi-center Study Of Talazoparib For Neoadjuvant Treatment Of Germline Brca1 / 2 Mutation Patients With Early Triple-negative Breast Cancer
Cancer Type
Breast Cancer
NCI ID
NCT03499353
Protocol IDs
C3441020
NCI-2018-01223
TALAZOPARIB NEOADJ BC
A Phase 2, Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600E-mutant Non-small Cell Lung Cancer
Cancer Type
Lung Cancer
NCI ID
NCT03915951
Protocol IDs
ARRAY-818-202
NCI-2019-02644
A Phase 2, Open-label, 2-arm, Response Rate Study Of Talazoparib In Men With Dna Repair Defects And Metastatic Castration-resistant Prostate Cancer Who Previously Received Taxane-based Chemotherapy And Progressed On At Least 1 Novel Hormonal Agent (Enzalutamide And / or Abiraterone Acetate / Prednisone)
Cancer Type
Prostate Cancer , Unknown Primary
NCI ID
NCT03148795
Protocol IDs
MDV3800-06
NCI-2017-01403
C3441006
2016-002036-32
A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement
Cancer Type
Eye Cancer, Leukemia
NCI ID
NCT03011372
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Cancer Type
Lymphoma, Multiple Myeloma
NCI ID
NCT02899052
Protocol IDs
M15-538
NCI-2016-01672
A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in Combination With Low Dose Cyclophosphamide and Pembrolizumab, in Subjects With Selected Advanced and Recurrent Solid Tumours.
Cancer Type
Lung Cancer, Ovarian Cancer, Unknown Primary
NCI ID
NCT03836352
Protocol IDs
P1719-SUR-Z11
NCI-2019-03013
Keynote 903
A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations
Cancer Type
Bladder Cancer, Kidney Cancer
NCI ID
NCT02872714
Protocol IDs
INCB 54828-201
NCI-2016-01513
A Phase 2, Prospective, Randomized, Open-Label Study on the Efficacy of Defibrotide Added to Standard of Care Immunoprophylaxis for the Prevention of Acute Graft-versus-Host-Disease in Adult and Pediatric Patients After Allogeneic Hematopietic Stem Cell Transplant
Cancer Type
Bone and Soft Tissue (including Sarcoma), Myelodysplastic Syndromes (MDS)
NCI ID
NCT03339297
Protocol IDs
JZP963-201
NCI-2018-00520
A Phase 2, Randomized, Biomarker-driven, Clinical Study on Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Cancer Type
Leukemia
NCI ID
NCT02520011
Protocol IDs
TPI-ALV-201
NCI-2015-02082
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCI ID
NCT03706365
Protocol IDs
Treatment Sites (13)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - Canton
Canton
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Kennestone
Marietta
Greta Dudley
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
A Phase 2, Randomized, Multi-Institutional Study of Nivolumab and Ipilimumab versus Nivolumab, Ipilimumab, and Stereotactic Body Radiation Therapy for Metastatic Merkel Cell Carcinoma
Cancer Type
Skin Cancer (Non-Melanoma)
NCI ID
NCT03071406
Protocol IDs
MCC-18786
NCI-2017-00427
A Phase 2, Randomized, Non-Comparative, Open-Label Study of NKTR-214 in Combination With Nivolumab and of Chemotherapy in Cisplatin Ineligible, Locally Advanced or Metastatic Urothelial Cancer Patients With Low PD-L1 Expression
Cancer Type
Bladder Cancer, Kidney Cancer, Unknown Primary
NCI ID
NCT03785925
Protocol IDs
18-214-10
NCI-2019-01752
CA045-012
A Phase 2, Randomized, Open-label Study of Nivolumab or Nivolumab / BMS-986205 Alone or Combined With Intravesical BCG in Participants With BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer
Cancer Type
Bladder Cancer
NCI ID
NCT03519256
Protocol IDs
CA209-9UT
NCI-2018-01177
2017-003581-27
A Phase 2, Single Arm, Multicenter, Open Label Trial Combining Optune with Concurrent Bevacizumab in the Setting of Recurrent or Progressive Meningioma
Cancer Type
Brain Cancer
NCI ID
NCT02847559
Protocol IDs
NU 16C02
NCI-2016-01026
STU00203030
A Phase 2, Single-Arm Study of Denosumab in Multiple Myeloma Patients with Renal Insufficiency
Cancer Type
Lymphoma, Multiple Myeloma
NCI ID
NCT02833610
Protocol IDs
15-571
NCI-2016-01375
A Phase 2, Single-arm, Open-label Study of Single-agent Brentuximab Vedotin for Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Cancer Type
Hodgkin Lymphoma
NCI ID
NCT01716806
Protocol IDs
SGN35-015
A Phase 2a, Open-Label, Multi-Center Study to Assess the Efficacy and Safety of Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Pembrolizumab in Subjects With Advanced Unresectable or Metastatic NSCLC Previously Treated With Anti-PD-1
Cancer Type
NCI ID
NCT04069936
Protocol IDs
CLN-P18001
NCI-2019-06384
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkin's Lymphoma
Cancer Type
Lymphoma
NCI ID
NCT02793583
Protocol IDs
UTX-TGR-205
NCI-2016-01433
A Phase 3 Randomized Double-Blind Placebo-Controlled Study Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Patients With Lower Risk Myelodysplastic Syndrome (MDS) With Low Red Blood Cell (RBC) Transfusion Burden (LTB)
Cancer Type
Myelodysplastic Syndromes (MDS)
NCI ID
NCT03263091
Protocol IDs
FGCL-4592-082
NCI-2017-02071
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
Cancer Type
NCI ID
NCT04166409
Protocol IDs
ACNS1833
ACNS1833
NCI-2019-07600
A Phase 3 Randomized Open Label Study to Compare NKTR-214 Combined With Nivolumab to the Investigator's Choice of Sunitinib or Cabozantinib in Patients With Previously Untreated Advanced Renal Cell Carcinoma
Cancer Type
Kidney Cancer, Unknown Primary
NCI ID
NCT03729245
Protocol IDs
17-214-09
NCI-2019-01389
CA045002
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Cancer Type
Kidney Cancer
NCI ID
NCT03055013
Protocol IDs
Treatment Sites (2)
Nancy N. and J.C. Lewis Cancer & Research Pavilion at St. Joseph's/Candler
Savannah
Alaina Underberg
912-819-5778
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
A Phase 3 Randomized Study of Selumetinib versus Carboplatin / Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
Cancer Type
NCI ID
NCT03871257
Protocol IDs
ACNS1831
ACNS1831
NCI-2019-01396
A Phase 3 randomized study to assess the efficacy and safety of Ublituximab in combination with TGR-1202 compared to Obinutuzumab in combination with Chlorambucil in patients with Chronic Lymphocytic Leukemia (CLL)
Cancer Type
Leukemia
NCI ID
NCT02656303
Protocol IDs
UTX-TGR-304
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Cancer Type
NCI ID
NCT03959085
Protocol IDs
AALL1732
AALL1732
NCI-2019-02845
A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine / Cisplatin Versus Placebo Plus Gemcitabine / Cisplatin as First-Line Therapy in Participants With Advanced and / or Unresectable Biliary Tract Carcinoma
Cancer Type
NCI ID
NCT04003636
Protocol IDs
3475-966
NCI-2019-05779
2019-000944-82
MK-3475-966
KEYNOTE-966
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL)
Cancer Type
Neuroblastoma
NCI ID
NCT03126916
Protocol IDs
ANBL1531
ANBL1531
NCI-2016-01734
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
Cancer Type
Germ Cell Tumor
NCI ID
NCT03067181
Protocol IDs
AGCT1531
AGCT1531
NCI-2017-00178
AGCT1531
A Phase 3 Study of Pembrolizumab in Combination With Carboplatin / Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab With or Without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Cancer Type
NCI ID
NCT03976362
Protocol IDs
7339-008
NCI-2019-03995
KEYLYNK-008
MK-7339-008
2018-004721-88
KEYLNK-008
194894
A Phase 3 Trial Investigating Blinatumomab ( NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)
Cancer Type
Lymphoma
NCI ID
NCT03914625
Protocol IDs
AALL1731
AALL1731
NCI-2019-02187
A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumors After Treatment With Imatinib
Cancer Type
Colon/Rectal Cancer
NCI ID
NCT03673501
Protocol IDs
Treatment Sites (2)
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination With Azacitidine in Subjects = 18 Years of Age With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
Cancer Type
NCI ID
NCT03173248
Protocol IDs
AG120-C-009
NCI-2017-02366
A Phase 3, Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Subjects With Red Blood Cell Transfusion-dependent Anemia and Thrombocytopenia Due to IPSS Lower-risk Myelodysplastic Syndromes.
Cancer Type
Myelodysplastic Syndromes (MDS)
NCI ID
NCT01566695
Protocol IDs
AZA-MDS-003
2012-002471-34
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
Cancer Type
NCI ID
NCT02927067
Protocol IDs
SHP620-302
NCI-2017-00422
2015-004726-34
A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Triplet Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)
Cancer Type
Lymphoma, Multiple Myeloma
NCI ID
NCT03651128
Protocol IDs
Treatment Sites (2)
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
Cancer Type
NCI ID
NCT02931539
Protocol IDs
SHP620-303
NCI-2016-01720
2015-004725-13
A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)
Cancer Type
NCI ID
NCT03656536
Protocol IDs
INCB 54828-302
NCI-2019-01725
A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant
Cancer Type
NCI ID
NCT02851407
Protocol IDs
15-007
NCI-2016-01249
A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in Participants With High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) That is Persistent or Recurrent Following BCG Induction (KEYNOTE-676)
Cancer Type
NCI ID
NCT03711032
Protocol IDs
3475-676
NCI-2019-00740
2018-001967-22
MK-3475-676
A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia
Cancer Type
Myelodysplastic Syndromes (MDS)
NCI ID
NCT03268954
Protocol IDs
Pevonedistat-3001
NCI-2017-02059
U1111-1189-8055
2017-000318-40
JapicCTI-183848
MOH_2018-02-04_002154
A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab Versus Placebo for Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
Cancer Type
NCI ID
NCT03383458
Protocol IDs
CA209-9DX
NCI-2018-00502
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Cancer Type
Prostate Cancer , Unknown Primary
NCI ID
NCT03395197
Protocol IDs
C3441021
NCI-2018-01651
TALAPRO-2
2017-003295-31
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants With High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (KEYNOTE-630)
Cancer Type
Skin Cancer (Non-Melanoma), Unknown Primary
NCI ID
NCT03833167
Protocol IDs
3475-630
NCI-2019-01629
MK-3475-630
2018-001974-76
KEYNOTE-630
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Superoxide Dismutase Mimetic GC4419 to Reduce Severe Oral Mucositis (SOM) Associated With Chemoradiotherapy for Locally Advanced, Non-Metastatic Head and Neck Cancer
Cancer Type
Unknown Primary
NCI ID
NCT03689712
Protocol IDs
GTI-4419-301
NCI-2018-02271
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia
Cancer Type
Leukemia
NCI ID
Protocol IDs
NCT01980875
A Phase 3, Randomized, Open-label Study of NKTR-214 Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Unresectable or Metastatic Melanoma
Cancer Type
Melanoma, Skin Cancer (Non-Melanoma), Unknown Primary
NCI ID
NCT03635983
Protocol IDs
CA045-001
NCI-2018-02224
17-214-08
2018-001423-40
A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-agent Maintenance Versus Rituximab Maintenance in Subjects With Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma
Cancer Type
Non-Hodgkin Lymphoma
NCI ID
NCT01996865
Protocol IDs
Treatment Sites (9)
Northwest Georgia Oncology Centers - Austell
Austell
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Bremen
Bremen
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Carrollton
Carrollton
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Cartersville
Cartersville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Douglasville
Douglasville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Jasper
Jasper
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Marietta
Marietta
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Paulding
Hiram
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Villa Rica
Villa Rica
Mary Gilley
770-281-5131
A Phase I / 2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors
Cancer Type
Bladder Cancer, Cervical Cancer, Kidney Cancer, Lung Cancer, Melanoma, Ovarian Cancer, Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Unknown Primary
NCI ID
NCT01968109
Protocol IDs
CA224-020
NCI-2014-00315
2014-002605-38
A Phase I / II Single Arm Open-Label Study to Explore Safety and Clinical Activity of GSK2857916 Administered in Combination With Pembrolizumab in Subjects With Relapsed / Refractory Multiple Myeloma (DREAMM 4)
Cancer Type
Lymphoma, Multiple Myeloma
NCI ID
NCT03848845
Protocol IDs
205207
NCI-2019-01291
A Phase I / II Study of Carfilzomib in Combination with R-CHOP (CR-CHOP) for Patients with Diffuse Large B-Cell Lymphoma
Cancer Type
Lymphoma
NCI ID
NCT02073097
Protocol IDs
CASE3413
NCI-2014-00249
A Phase I / II Study of Concurrent Cetuximab and Nivolumab in Patients with Recurrent and / or Metastatic Head and Neck Squamous Cell Carcinoma
Cancer Type
Head and Neck Cancer, Oral Cancer, Unknown Primary
NCI ID
NCT03370276
Protocol IDs
MCC-19178
NCI-2017-02373
A Phase I / II Study of Gemcitabine, Bendamustine, and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma
Cancer Type
Lymphoma
NCI ID
NCT03739619
Protocol IDs
Winship4388-18
NCI-2018-02221
IRB00104033
A Phase I / II Study of Ixazomib and Ibrutinib in Relapsed / Refractory Mantle Cell Lymphoma
Cancer Type
Lymphoma
NCI ID
NCT03323151
Protocol IDs
PrE0404
NCI-2017-02399
X16077
A Phase I / II Study of Nivolumab in Combination With 5-azacytidine in Pediatric Patients With Relapsed / Refractory Acute Myeloid Leukemia (BMS Reference CA209-9JY)
Cancer Type
NCI ID
NCT03825367
Protocol IDs
T2016-002
NCI-2019-06317
A Phase I / II Study of Pembrolizumab (MK-3475) in Children With Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma (KEYNOTE-051)
Cancer Type
Neuroblastoma
NCI ID
NCT02332668
Protocol IDs
3475-051
NCI-2015-00528
2014-002950-38
A Phase I / II Study of SEL24 in Patients With Acute Myeloid Leukemia
Cancer Type
NCI ID
NCT03008187
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
A Phase I / II Study of the PD-1 Antibody Nivolumab in Combination with Lenalidomide in Relapsed / Refractory Non-Hodgkin’s Lymphoma (NHL) and Hodgkin’s Disease (HD)
Cancer Type
NCI ID
NCT03015896
Protocol IDs
OSU-16167
NCI-2016-01966
2016C0166
A Phase I / II Study of Trifluridine / Tipiracil (TAS102) in Combination with Nanoliposomal Irinotecan (NAL-IRI) in Advanced GI Cancers
Cancer Type
Pancreatic Cancer, Stomach/ Gastric Cancer, Unknown Primary
NCI ID
NCT03368963
Protocol IDs
Winship4146-17
NCI-2017-01661
IRB00098958
A Phase I / II Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Patients With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma Who Are Unable to Tolerate Full-Dose Chemotherapy
Cancer Type
Lymphoma
NCI ID
NCT03677154
Protocol IDs
GO40554
NCI-2019-00169
A Phase I / II Trial of the PD-L1 Inhibitor, Durvalumab (MEDI4736) plus CV301 in Combination with Maintenance Chemotherapy for Patients with Metastatic Colorectal or Pancreatic Adenocarcinoma
Cancer Type
Pancreatic Cancer, Unknown Primary
NCI ID
NCT03376659
Protocol IDs
2017-1189
NCI-2017-02486
A Phase I / II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed / Refractory Multiple Myeloma - DREAMM-6
Cancer Type
Lymphoma, Multiple Myeloma
NCI ID
NCT03544281
Protocol IDs
207497
NCI-2018-01516
A Phase I and Surgical Study of Ribociclib and Everolimus (RAD001) in Children with Recurrent or Refractory Malignant Brain Tumors
Cancer Type
Brain Cancer
NCI ID
NCT03387020
Protocol IDs
PBTC-050
PBTC-050
NCI-2017-02079
A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED / REFRACTORY SMALL CELL LUNG CANCER (SCLC), CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)
Cancer Type
NCI ID
NCT03460977
Protocol IDs
C2321001
NCI-2018-01985
A Phase I Dose Escalation Study of Autologous Expanded Natural Killer (NK) Cells for Immunotherapy of Relapsed Refractory Neuroblastoma With Dinutuximab + / - Lenalidomide
Cancer Type
Neuroblastoma, Unknown Primary
NCI ID
NCT02573896
Protocol IDs
NANT 2013-01
NCI-2019-00106
A Phase I Dose Escalation Study of the Safety, Pharmacokinetics and Pharmacodynamics of MRX-2843 in Adult Subjects With Relapsed / Refractory Advanced and / or Metastatic Solid Tumors
Cancer Type
Unknown Primary
NCI ID
NCT03510104
Protocol IDs
2843-1001
NCI-2018-01102
A Phase I Open Label Clinical Trial Evaluating the Safety and Anti-Tumor Activity of Autologous T Cells Expressing Enhanced TCRs Specific for Alpha Fetoprotein (AFP?³³²T) in HLA-A2 Positive Subjects With Advanced Hepatocellular Carcinoma (HCC)
Cancer Type
NCI ID
NCT03132792
Protocol IDs
ADP-0033-001
NCI-2017-01188
A PHASE I OPEN-LABEL PHARMACOKINETICS AND SAFETY STUDY OF TALAZOPARIB (MDV3800) IN PATIENTS WITH ADVANCED SOLID TUMORS AND NORMAL OR VARYING DEGREES OF HEPATIC IMPAIRMENT
Cancer Type
Unknown Primary
NCI ID
NCT02997176
Protocol IDs
MDV3800-02
NCI-2017-00161
C3441002
A Phase I Study of 131I-MIBG With Dinutuximab for Relapsed / Refractory Neuroblastoma
Cancer Type
Neuroblastoma
NCI ID
NCT03332667
Protocol IDs
NANT2017-01
NCI-2018-01160
A Phase I Study of FOR46 Administered Every 21 Days in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Cancer Type
Lymphoma, Multiple Myeloma
NCI ID
NCT03650491
Protocol IDs
FOR46-002
NCI-2018-02600
A Phase I Study of Mesenchymal Stromal Cells for the Treatment of Acute and Chronic Graft versus Host Disease
Cancer Type
Bone and Soft Tissue (including Sarcoma)
NCI ID
NCT02359929
Protocol IDs
EPIC2014-MSC002
NCI-2015-00170
EPIC-MSC002
A Phase I Study of Neihulizumab (AbGn-168H) in Patients With Steroid-refractory Acute Graft-versus-host Disease (Sr-aGvHD)
Cancer Type
Bone and Soft Tissue (including Sarcoma)
NCI ID
NCT03327857
Protocol IDs
2017.002.01
NCI-2018-01343
A Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma
Cancer Type
Lymphoma
NCI ID
NCT02992522
Protocol IDs
OSU-16187
NCI-2016-01723
2016C0150
A Phase I Study of VX-970 in Combination with Cisplatin and XRT in Patients with Locally Advanced HPV (-) Head and Neck Squamous Cell Carcinoma (HNSCC; SDC 10060121)
Cancer Type
Head and Neck Cancer, Oral Cancer
NCI ID
NCT02567422
Protocol IDs
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
A Phase I Study With an Expansion Cohort of the Combination of Ipilimumab and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma
Cancer Type
Hodgkin Lymphoma
NCI ID
NCT01896999
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
A Phase I Trial of AZD9291 and Necitumumab in EGFR-Mutant Non-Small Cell Lung Cancer after Progression on a Previous EGFR Tyrosine Kinase Inhibitor
Cancer Type
NCI ID
NCT02496663
Protocol IDs
9898
9898
NCI-2015-01053
PHI-77
A Phase I Trial of Temsirolimus (CCI-779, Pfizer, Inc.) in Combination With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
Cancer Type
Acute Lymphoblastic Leukemia, Non-Hodgkin Lymphoma
NCI ID
NCT01614197
Protocol IDs
T2014-001
NCI-2012-01493
T2008-004
A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients with Relapsed or Refractory Non-Hodgkins Lymphoma (NHL)
Cancer Type
Lymphoma
NCI ID
NCT02568553
Protocol IDs
9924
9924
NCI-2015-01640
PHI-79
A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Cancer Type
Leukemia, Myelodysplastic Syndromes (MDS)
NCI ID
NCT02074839
Protocol IDs
AG120-C-001
NCI-2014-00720
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Avelumab (MSB0010718C) in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Cancer Type
Kidney Cancer
NCI ID
NCT01772004
Protocol IDs
EMR 100070-001
2013-002834-19
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Avelumab (MSB0010718C) in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Cancer Type
Head and Neck Cancer
NCI ID
NCT01772004
Protocol IDs
EMR 100070-001
2013-002834-19
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Cancer Type
Solid Tumor
NCI ID
NCT01772004
Protocol IDs
Treatment Sites (1)
University Cancer and Blood Center, LLC - Athens Medical Oncology
Athens
Jamie Hodgson
706-353-2990 x279
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Cancer Type
Breast Cancer
NCI ID
NCT01772004
Protocol IDs
EMR 100070-001
2013-002834-19
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Cancer Type
Stomach/ Gastric Cancer
NCI ID
NCT01772004
Protocol IDs
EMR 100070-001
2013-002834-19
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Cancer Type
Melanoma
NCI ID
NCT01772004
Protocol IDs
EMR 100070-001
2013-002834-19
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Cancer Type
Ovarian Cancer
NCI ID
NCT01772004
Protocol IDs
Treatment Sites (9)
Northwest Georgia Oncology Centers - Austell
Austell
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Bremen
Bremen
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Carrollton
Carrollton
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Cartersville
Cartersville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Douglasville
Douglasville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Jasper
Jasper
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Marietta
Marietta
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Paulding
Hiram
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Villa Rica
Villa Rica
Mary Gilley
770-281-5131
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Cancer Type
Adrenal Cancer
NCI ID
NCT01772004
Protocol IDs
EMR 100070-001
2013-002834-19
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Cancer Type
Mesothelioma
NCI ID
NCT01772004
Protocol IDs
EMR 100070-001
2013-002834-19
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Cancer Type
Bladder Cancer
NCI ID
NCT01772004
Protocol IDs
EMR 100070-001
2013-002834-19
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability,Pharmacokinetics, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Cancer Type
Unknown Primary
NCI ID
NCT02517398
Protocol IDs
EMR 200647-001
NCI-2015-01980
A Phase I/II Study of MLN9708 as Post-Transplant Maintenance for Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplant in First Remission
Cancer Type
Non-Hodgkin Lymphoma
NCI ID
NCT02632396
Protocol IDs
Winship2839-15
NCI-2015-01943
IRB00076016
Winship2839-15 (X16058)
X16058
A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor-Based Therapy
Cancer Type
Multiple Myeloma, Unknown Primary
NCI ID
NCT02004275
Protocol IDs
A061202
NCI-2013-01702
CALGB-A061202
A Phase Ia / Ib Open-Label, Multicenter Study Evaluating The Safety and Pharmacokinetics of Tiragolumab as a Single Agent and In Combination With Daratumumab In Patients With Relapsed Or Refractory Multiple Myeloma, and As a Single Agent and In Combination With Rituximab In Patients With Relapsed Or Refractory B-Cell Non-Hodgkin Lymphoma
Cancer Type
NCI ID
NCT04045028
Protocol IDs
GO41036
NCI-2019-06145
A Phase Ib Dose Escalation and Expansion, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of APTO-253 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia or High-Risk Myelodysplasia
Cancer Type
Myelodysplastic Syndromes (MDS)
NCI ID
NCT02267863
Protocol IDs
253-HEM1-01
NCI-2014-02507
A Phase IB Study of Blinatumomab in Patients with Pre B-Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) as Post-Allogeneic Stem Cell Transplant (Allo-HSCT) Remission Maintenance
Cancer Type
Lymphoma
NCI ID
NCT03114865
Protocol IDs
J1713
NCI-2019-00402
CRMS-65830
IRB00125679
A Phase Ib Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
Cancer Type
NCI ID
NCT03816345
Protocol IDs
10204
10204
NCI-2019-00241
A Phase Ib Trial of Neoadjuvant AMG-232 Concurrent with Preoperative Radiotherapy in Wild-Type P53 Soft Tissue Sarcoma (STS)
Cancer Type
NCI ID
NCT03217266
Protocol IDs
NRG-DT001
NRG-DT001
NCI-2017-01234
A Phase Ib/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination With Polatuzumab Vedotin and Venetoclax in Patients With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
Cancer Type
Non-Hodgkin Lymphoma
NCI ID
NCT02611323
Protocol IDs
GO29833
NCI-2015-02093
2015-001998-40
A Phase Ib/II Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330), Gemcitabine and Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer
Cancer Type
Pancreatic Cancer
NCI ID
NCT02178436
Protocol IDs
2013-133
NCI-2014-01249
1403012942
A Phase II / III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA
Cancer Type
Head and Neck Cancer
NCI ID
NCT03811015
Protocol IDs
EA3161
EA3161
NCI-2019-00179
A Phase II / III Study of Peri-Operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
Cancer Type
Colon/Rectal Cancer
NCI ID
NCT03604991
Protocol IDs
EA2174
EA2174
NCI-2018-01575
A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unresectable Desmoplastic Melanoma (DM)
Cancer Type
Bone and Soft Tissue (including Sarcoma), Melanoma
NCI ID
NCT02775851
Protocol IDs
Treatment Sites (2)
Low Country Cancer Care Associates, PC
Savannah
Nancy N. and J.C. Lewis Cancer & Research Pavilion at St. Joseph's/Candler
Savannah
Alaina Underberg
912-819-5778
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
Cancer Type
Colon/Rectal Cancer
NCI ID
NCT02921256
Protocol IDs
Treatment Sites (1)
Nancy N. and J.C. Lewis Cancer & Research Pavilion at St. Joseph's/Candler
Savannah
Alaina Underberg
912-819-5778
A Phase II Evaluation of Bendamustine, Obinutuzumab and Venetoclax in Patients with Untreated Mantle Cell Lymphoma
Cancer Type
Lymphoma
NCI ID
NCT03872180
Protocol IDs
Winship4363-18
NCI-2018-00995
IRB00102827
A Phase II Multi-Institutional Study of Concurrent Radiotherapy, Palbociclib, and Hormone Therapy for Treatment of Bone Metastasis in Breast Cancer Patients
Cancer Type
Breast Cancer, Unknown Primary
NCI ID
NCT03691493
Protocol IDs
Treatment Sites (17)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Atlanta Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - Canton
Canton
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Kennestone
Marietta
Greta Dudley
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Georgia Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Northside Hospital Cancer Institute - Forsyth
Cumming
404-303-3355
University Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
A Phase II Randomized Study of Adjuvant versus NeoAdjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High-Risk Melanoma
Cancer Type
Melanoma, Skin Cancer (Non-Melanoma)
NCI ID
NCT03698019
Protocol IDs
Treatment Sites (1)
Nancy N. and J.C. Lewis Cancer & Research Pavilion at St. Joseph's/Candler
Savannah
Alaina Underberg
912-819-5778
A Phase II Randomized Study of Ramucirumab plus MK3475 (Pembrolizumab) versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
Cancer Type
Lung Cancer
NCI ID
NCT03971474
Protocol IDs
Treatment Sites (13)